Please login to the form below
Oxford University
This page shows the latest Oxford University news and features for those working in and with pharma, biotech and healthcare.
AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
Earlier this month, The Wall Street Journal reported that AZ, The University of Oxford and Johnson &Johnson, alongside outside scientists, are planning to conduct early research into the potential of modifications
Latest news
-
Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
The first results from the Oxford University-led study suggest that two mixed schedules – a first dose of the Pfizer/BioNTech vaccine followed by the AstraZeneca/Oxford University vaccine or a ... first dose of the AstraZeneca/Oxford University vaccine
-
AZ, J&J to research modifications to COVID-19 vaccines over rare blood clot issues
J&J, AZ and the University of Oxford, alongside outside scientists, are planning to conduct early research into the potential of modifications to their vaccines to reduce or remove the risk
-
Study finds mixed vaccine schedules provide strong immune response against COVID-19
Mixing COVID-19 vaccines as part of a two-dose schedule generates a strong immune response against the SARS-CoV-2 virus, a study led by Oxford University suggests. ... the AstraZeneca/Oxford University vaccine followed by the Pfizer/BioNTech vaccine –
-
Oxford University to study antiparasitic drug ivermectin in COVID-19 trial
Researchers from the University of Oxford are planning to investigate the antiparasitic drug ivermectin as part of the PRINCIPLE trial – a large-scale clinical trial evaluating possible at-home COVID-19 ... In a statement, Oxford University said that
-
EU takes legal steps against AZ over delayed COVID-19 vaccine deliveries
The EU has alleged that AZ has failed to deliver the promised amount of doses of its Oxford University-partnered vaccine, with the initial dispute originating in January when the pharma
Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
AZ, J&J to research modifications to COVID-19 vaccines over rare blood clot issues
Oxford University to study antiparasitic drug ivermectin in COVID-19 trial
EU takes legal steps against AZ over delayed COVID-19 vaccine deliveries
More from news
Approximately 34 fully matching, plus 172 partially matching documents found.
Latest Intelligence
-
Rare genetic diseases – what’s in store for 2021?
So far the Pfizer/BioNTech, Moderna and AstraZeneca/Oxford University vaccines have all received approval in the UK and other countries for the very disease that put all these changes into
-
COVID-19: the race to find a vaccine
Multiple groups are advancing vaccines based on similar technology. University of Oxford researchers are enrolling volunteers in a trial of its adenovirus vaccine, while Johnson &Johnson and the US government have
-
Developing a COVID-19 vaccine
Researchers from Oxford University have also said they plan to start clinical trials of their COVID-19 vaccine this month. ... The CEPI has currently initiated eight COVID-19 vaccine developments with Curevac, Inovio Pharmaceuticals, Moderna, Novavax,
-
War games: why brand teams need a cunning plan that cannot fail
Who knows, it might well have been ‘as cunning as a fox who’d just been appointed Professor of Cunning at Oxford University’ – but his comrades never got to hear it
-
Biotech profile: Tom Evans, CEO, Vaccitech.
Vaccitech was launched in a spin-out from Oxford University in May 2016, with the aim of using its novel technology platform to develop a range of innovative new vaccines. ... You took the helm of Vaccitech when it was spun out Oxford University
Rare genetic diseases – what’s in store for 2021?
COVID-19: the race to find a vaccine
Developing a COVID-19 vaccine
War games: why brand teams need a cunning plan that cannot fail
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest appointments
-
Amanda Pritchard becomes NHS England’s first female chief executive
She first joined the NHS as a graduate management trainee in 1997 after graduating from Oxford University.
-
Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more
Ian Walmsey, Pro-Vice-Chancellor Research &Innovation at the University of Oxford and Chair of the RFI’s Interim Board said: “I am delighted that Vivienne has agreed to be the ... I’ve seen how siloed some parts of science and corporate R&D can be
-
Paul Stockdale joins Oxford BioDynamics as CFO
He takes over from Katie Long, who has returned to her role within Tessera Investment Management, having previously established and led Oxford BioDynamics’ finance function. ... A spin-out from Oxford University, Oxford BioDynamics focuses on the
-
Martin Reeves joins Oxford BioDynamics
He takes up a senior vice president role. Oxford BioDynamics – a spin out company from the University of Oxford – has appointed Martin Reeves as its new senior vice president, commercial development. ... Christian Hoyer Millar, CEO at Oxford
-
Consilium appoints executive consultants
Standage (pictured right) joins the strategic healthcare communications firm from the University of Cambridge Judge Business School, having recently graduated with a degree in modern languages and management studies. ... Meanwhile Phillips (pictured left)
Amanda Pritchard becomes NHS England’s first female chief executive
Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more
Paul Stockdale joins Oxford BioDynamics as CFO
Martin Reeves joins Oxford BioDynamics
Consilium appoints executive consultants
More from appointments
Approximately 0 fully matching, plus 16 partially matching documents found.
Latest from PMHub
-
WHITE PAPER: From bench to bedside in one year - how the race for a COVID-19 vaccine will change the future of drug development
One group involved in this area of research was the team at Oxford University, who’s efforts eventually became the Oxford-AstraZeneca vaccine currently in circulation. ... In the past year, we have seen partnerships between companies such as Pfizer and
-
Communicating the vaccine: how do we get the story right?
How significant are the barriers? According to a recent poll conducted by the University of Oxford, while a substantial majority (72%) are in favour of a COVID-19 vaccine, 16% of
-
Is the world ready for a COVID-19 vaccine?
Since this initial announcement, other good news in vaccine development has followed, with companies and collaborations, including Moderna and the AstraZeneca/University of Oxford team, publishing similarly positive trial results.
-
September 2020: diversity and inclusion in clinical trials round-up
population. There is the same problem in Europe.” Luis E. Raez, MD, of Memorial Cancer Institute/Florida International University in Miami, one of the co-authors. ... The trial is taking place in the UK, led by the University of Oxford.
-
Oxford University Press
Oxford University Press adds new innovative ePrint options to its product portfolio for healthcare marketing and education. ... Oxford University Press advertising and custom content team hosts their first ever virtual drop-in sessions.
WHITE PAPER: From bench to bedside in one year - how the race for a COVID-19 vaccine will change the future of drug development
Communicating the vaccine: how do we get the story right?
September 2020: diversity and inclusion in clinical trials round-up
Oxford University Press
More from PMHub
Approximately 0 fully matching, plus 25 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
-
Digital account director
-
Competitive
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Distracted boyfriend: the secret of a successful long-distance relationship
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
No results were found
PMHub
Accession
Accession was a born from a passion and a vision. A passion to harness the power of market access to...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
